Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
Autore:
Kawahara, M; Furuse, K; Segawa, Y; Yoshimori, K; Matsui, K; Kudoh, S; Hasegawa, K; Niitani, H;
Indirizzi:
Natl Kinki Cent Hosp Chest Dis, Dept Internal Med, Osaka, Japan Natl KinkiCent Hosp Chest Dis Osaka Japan t Internal Med, Osaka, Japan Natl Shikoku Canc Ctr Hosp, Dept Internal Med, Matsuyama, Ehime, Japan Natl Shikoku Canc Ctr Hosp Matsuyama Ehime Japan Matsuyama, Ehime, Japan Fukujuji Hosp, Japan AntiTB Assoc, Dept Resp Organs, Tokyo, Japan FukujujiHosp Tokyo Japan AntiTB Assoc, Dept Resp Organs, Tokyo, Japan Osaka Prefectural Habikino Hosp, Dept Internal Med 2, Osaka, Japan Osaka Prefectural Habikino Hosp Osaka Japan nternal Med 2, Osaka, Japan Nippon Med Coll, Dept Internal Med 4, Tokyo, Japan Nippon Med Coll TokyoJapan Med Coll, Dept Internal Med 4, Tokyo, Japan Jizankai Tsuboi Hosp, Dept Internal Med, Fukushima, Japan Jizankai Tsuboi Hosp Fukushima Japan ept Internal Med, Fukushima, Japan Tokyo Cooperat Oncol Grp, Tokyo, Japan Tokyo Cooperat Oncol Grp Tokyo Japan o Cooperat Oncol Grp, Tokyo, Japan
Titolo Testata:
BRITISH JOURNAL OF CANCER
fascicolo: 7, volume: 85, anno: 2001,
pagine: 939 - 943
SICI:
0007-0920(20010928)85:7<939:PISOSA>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONTINUOUS INFUSION; ANTITUMOR-ACTIVITY; 5-FLUOROURACIL; CHEMOTHERAPY; CISPLATIN; CARCINOMA; BOLUS; TEGAFUR; PLASMA; URACIL;
Keywords:
NSCLC; tegafur; CDHP; S-1;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Kawahara, M Natl Kinki Cent Hosp Chest Dis, Dept Internal Med, Osaka, Japan Natl Kinki Cent Hosp Chest Dis Osaka Japan ed, Osaka, Japan
Citazione:
M. Kawahara et al., "Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer", BR J CANC, 85(7), 2001, pp. 939-943

Abstract

The purpose of this study was to evaluate the efficacy and safety of a novel oral anticancer fluoropyrimidine derivative, S-1, in patients receiving initial chemotherapy for unresectable, advanced non-small-cell lung cancer (NSCLC). Between June 1996 and July 1998, 62 patients with NSCLC who had not received previous chemotherapy for advanced disease were enrolled in thisstudy. 59 patients (22 stage IIIB and 37 stage IV) were eligible for the evaluation of efficacy and safety. S-1 was administered orally, twice daily,after meals. 3 dosages of S-1 were prescribed according to body surface area (BSA) so that they would be approximately equivalent to 80 mg m(-2) day(-1): BSA < 1.25 m(2), 40 mg b.i.d.; BSA : 1.25 but <1.5 m(2); 50 mg b.i.d.,and BSA greater than or equal to 1.5 m(2): 60 mg b.i.d. One cycle consisted of consecutive administration of S-1 for 28 days followed by a 2-week rest period, and cycles were repeated up to 4 times. The partial response (PR)rate of the eligible patients was 22.0% (13/59); (95% confidence interval:12.3-34.7%). A PR was observed in 22.7% (5/22) of the stage IIIB patients and 21.6% (8/37) of the stage IV patients. The median response duration was3.4 months (1.1-13.7 months or longer). Grade 4 neutropenia was observed in one of the 59 patients (11.7%). The grade 3 or 4 toxicities consisted of decreased haemoglobin level in 1.7% of patients (1/59), neutropenia in 6.8%(4/59), thrombocytopenia in 1.7% (1/59), anorexia in 10.2% (6/59), diarrhoea in 8.5% (5/59), stomatitis in 1.7% (1/59), and malaise in 6.8% (4/59), and their incidences were relatively low. There were no irreversible, severeor unexpected toxicities. The median survival time (MST) of all patients was 10.2 months (95% confidence interval: 7.7-14.5 months), and the one-yearsurvival rate was 41.1%. The MST of the stage IIIB patients was 7.9 months, and that of the stage IV patients was 11.1 months. The one-year survival rates of the stage IIIB and IV patients were 30.7% and 47.4%, respectively. S-1 was considered to be an active single agent against NSCLC. Further study of S-1 with other active agents is warranted. (C) 2001 Cancer Research Campaign http://www.bjcancer.com.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 23:11:49